The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Lamotrigine SyriMed 5mg/ml Oral Suspension



Syri Pharma Limited t/a Thame LaboratoriesPA22697/018/001

Main Information

Trade NameLamotrigine SyriMed 5mg/ml Oral Suspension
Active SubstancesLamotrigine
Dosage FormOral suspension
Licence HolderSyri Pharma Limited t/a Thame Laboratories
Licence NumberPA22697/018/001

Group Information

ATC CodeN03AX09 lamotrigine

Status

License statusAuthorised
Licence Issued02/09/2022
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportPDF Version
« Back